Association of PIN3 16-bp duplication polymorphism of TP53 with breast cancer risk in Mali and a meta-analysis.
Adult
Base Pairing
/ genetics
Breast Neoplasms
/ genetics
Case-Control Studies
Female
Genetic Association Studies
Genetic Heterogeneity
Genetic Predisposition to Disease
Humans
Mali
Models, Genetic
Odds Ratio
Polymorphism, Genetic
Publication Bias
Risk Factors
Tumor Suppressor Protein p53
/ genetics
Breast cancer
Malian population
Meta-analysis
PIN316-bp duplication
TP53
Journal
BMC medical genetics
ISSN: 1471-2350
Titre abrégé: BMC Med Genet
Pays: England
ID NLM: 100968552
Informations de publication
Date de publication:
03 07 2020
03 07 2020
Historique:
received:
20
11
2019
accepted:
18
06
2020
entrez:
5
7
2020
pubmed:
6
7
2020
medline:
29
10
2020
Statut:
epublish
Résumé
Breast cancer, the most common tumor in women in Mali and worldwide has been linked to several risk factors, including genetic factors, such as the PIN3 16-bp duplication polymorphism of TP53. The aim of our study was to evaluate the role of the PIN3 16-bp duplication polymorphism in the susceptibility to breast cancer in the Malian population and to perform a meta-analysis to better understand the correlation with data from other populations. We analyzed the PIN3 16-bp duplication polymorphism in blood samples of 60 Malian women with breast cancer and 60 healthy Malian women using PCR. In addition, we performed a meta-analysis of case-control study data from international databases, including Pubmed, Harvard University Library, Genetics Medical Literature Database, Genesis Library and Web of Science. Overall, odds ratio (OR) with 95% CI from fixed and random effects models were determined. Inconsistency was used to assess heterogeneity between studies and publication bias was estimated using the funnel plot. In the studied Malian patients, a significant association of PIN3 16-bp duplication polymorphism with breast cancer risk was observed in dominant (A1A2 + A2A2 vs. A1A1: OR = 2.26, CI 95% = 1.08-4.73; P = 0.02) and additive (A2 vs. A1: OR = 1.87, CI 95% = 1.05-3.33; P = 0.03) models, but not in the recessive model (P = 0.38). In the meta-analysis, nineteen (19) articles were included with a total of 6018 disease cases and 4456 controls. Except for the dominant model (P = 0.15), an increased risk of breast cancer was detected with the recessive (OR = 1.46, 95% CI = 1.15-1.85; P = 0.002) and additive (OR = 1.11, 95% CI = 1.02-1.19; P = 0.01) models. The case-control study showed that PIN3 16-bp duplication polymorphism of TP53 is a significant risk factor for breast cancer in Malian women. These findings are supported by data from the meta-analysis carried out on different ethnic groups around the world.
Sections du résumé
BACKGROUND
Breast cancer, the most common tumor in women in Mali and worldwide has been linked to several risk factors, including genetic factors, such as the PIN3 16-bp duplication polymorphism of TP53. The aim of our study was to evaluate the role of the PIN3 16-bp duplication polymorphism in the susceptibility to breast cancer in the Malian population and to perform a meta-analysis to better understand the correlation with data from other populations.
METHODS
We analyzed the PIN3 16-bp duplication polymorphism in blood samples of 60 Malian women with breast cancer and 60 healthy Malian women using PCR. In addition, we performed a meta-analysis of case-control study data from international databases, including Pubmed, Harvard University Library, Genetics Medical Literature Database, Genesis Library and Web of Science. Overall, odds ratio (OR) with 95% CI from fixed and random effects models were determined. Inconsistency was used to assess heterogeneity between studies and publication bias was estimated using the funnel plot.
RESULTS
In the studied Malian patients, a significant association of PIN3 16-bp duplication polymorphism with breast cancer risk was observed in dominant (A1A2 + A2A2 vs. A1A1: OR = 2.26, CI 95% = 1.08-4.73; P = 0.02) and additive (A2 vs. A1: OR = 1.87, CI 95% = 1.05-3.33; P = 0.03) models, but not in the recessive model (P = 0.38). In the meta-analysis, nineteen (19) articles were included with a total of 6018 disease cases and 4456 controls. Except for the dominant model (P = 0.15), an increased risk of breast cancer was detected with the recessive (OR = 1.46, 95% CI = 1.15-1.85; P = 0.002) and additive (OR = 1.11, 95% CI = 1.02-1.19; P = 0.01) models.
CONCLUSION
The case-control study showed that PIN3 16-bp duplication polymorphism of TP53 is a significant risk factor for breast cancer in Malian women. These findings are supported by data from the meta-analysis carried out on different ethnic groups around the world.
Identifiants
pubmed: 32620097
doi: 10.1186/s12881-020-01072-4
pii: 10.1186/s12881-020-01072-4
pmc: PMC7333399
doi:
Substances chimiques
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
142Subventions
Organisme : FIC NIH HHS
ID : D43 TW010543
Pays : United States
Organisme : FIC NIH HHS
ID : U2R TW010673
Pays : United States
Références
Asian Pac J Cancer Prev. 2015;16(7):2971-4
pubmed: 25854391
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
J Natl Cancer Inst. 1992 Feb 19;84(4):246-52
pubmed: 1734086
Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1495-506
pubmed: 26359465
Biomed Rep. 2016 Mar;4(3):282-292
pubmed: 26998264
Cancer Detect Prev. 2007;31(3):207-13
pubmed: 17574348
Mutat Res. 1997 Nov 28;381(2):201-7
pubmed: 9434876
Cancer Epidemiol Biomarkers Prev. 1997 Feb;6(2):105-12
pubmed: 9037561
Indian J Cancer. 2011 Jul-Sep;48(3):298-302
pubmed: 21921327
Cancer Detect Prev. 2008;32(2):140-3
pubmed: 18640791
J Natl Cancer Inst. 2002 May 1;94(9):681-90
pubmed: 11983757
Mol Cell Biol. 1986 May;6(5):1379-85
pubmed: 2946935
Cell Death Dis. 2013 Feb 14;4:e492
pubmed: 23412385
BMC Cancer. 2008 Jan 29;8:32
pubmed: 18230179
Oncogene. 1996 Nov 21;13(10):2159-66
pubmed: 8950983
Oncogene. 2002 Oct 3;21(44):6722-8
pubmed: 12360399
Mol Cell Biol. 2004 Sep;24(18):7987-97
pubmed: 15340061
Breast Cancer Res Treat. 2016 Jul;158(2):219-32
pubmed: 27372070
PLoS One. 2013 Apr 19;8(4):e61662
pubmed: 23620777
Med Oncol. 2011 Sep;28(3):709-15
pubmed: 20443084
Breast Cancer Res Treat. 2010 Apr;120(2):509-17
pubmed: 19629678
Pathol Oncol Res. 2009 Sep;15(3):359-68
pubmed: 19048399
Breast Cancer Res Treat. 2010 Apr;120(3):705-14
pubmed: 19657731
Int J Cancer. 2003 Jan 20;103(3):431-3
pubmed: 12471629
Oncogene. 1993 Jun;8(6):1703-5
pubmed: 8502490
Oncol Rep. 2009 Nov;22(5):1205-11
pubmed: 19787241
Breast Cancer Res Treat. 2019 Feb;173(3):727-733
pubmed: 30430302
Biol Res. 2017 Oct 6;50(1):35
pubmed: 28985766
Breast Cancer Res Treat. 2010 Jan;119(1):201-11
pubmed: 19360465
PLoS One. 2015 Jul 30;10(7):e0134463
pubmed: 26226484
Cancer Epidemiol. 2010 Apr;34(2):184-8
pubmed: 20233677
Oncol Lett. 2017 Apr;13(4):2483-2489
pubmed: 28454424
PLoS One. 2019 Aug 6;14(8):e0220727
pubmed: 31387111
Asian Pac J Cancer Prev. 2014;15(6):2631-4
pubmed: 24761875
Eur J Med Res. 2018 Oct 11;23(1):47
pubmed: 30309383
Oncogene. 2004 Mar 11;23(10):1954-6
pubmed: 14647431
J Clin Invest. 1999 Aug;104(3):263-9
pubmed: 10430607
Eur J Gynaecol Oncol. 2010;31(5):539-44
pubmed: 21061796
Med Sci (Paris). 2007 Nov;23(11):1021-3
pubmed: 18021719
Tumour Biol. 2014 Dec;35(12):12403-8
pubmed: 25201062
Asian Pac J Cancer Prev. 2012;13(7):3305-11
pubmed: 22994752
Nature. 1986 Mar 6-12;320(6057):84-5
pubmed: 3456488
Asian Pac J Cancer Prev. 2014;15(16):6871-9
pubmed: 25169539
Pharmacogenetics. 2002 Apr;12(3):269-72
pubmed: 11927843
DNA Cell Biol. 2012 Mar;31(3):306-16
pubmed: 21838531
Breast Cancer Res Treat. 2008 Mar;108(1):93-9
pubmed: 17624591